ロブ・アーノルド
エグゼクティブ・バイスプレジデント
Expertise:
"欧州、北米、アジアで30年以上にわたるコンサルティングおよびエグゼクティブリーダーシップを経験してきたロブ・アーノルドは、ライフサイエンスで最も困難な部類のビジネス状況に対処するための創造的ソリューションの開発に携わってきました。ロブは現在、ポートフォリオ管理やライフサイエンス分野の複数の大手企業のリダイレクションなど、イノベーションとトランスフォーメーションを担当しています。
ロブは、ライフサイエンスの戦略に関する業界フォーラム、ビジネススクール、専門家協会で講演し、多くの専門論文を発表しています。
ダートマス大学のエイモス・タック・スクールでMBAを取得し、ケンブリッジ大学で修士号を取得しています。"
Articles by ロブ・アーノルド
Establishing the Pricing and Value Proposition of AI/MedTech Solutions in Healthcare
Authors: Prachi Singh, Senior Consultant; Robin Arnold, EVP, APAC Consulting Unlock the future of healthcare with our white paper, “Establishing the Pricing and Value Proposition of AI/MedTech Solutions in Healthcare.” Discover the essential components of pricing AI/MedTech solutions and crafting compelling value propositions that resonate with stakeholders, including payers, patients, and physicians. Explore real-world examples, such as AI in breast cancer screening, to understand the complexities of pricing models and the significance of local evidence in driving successful adoption. With a comprehensive analysis of performance, validation, usability, regulatory compliance and cost-savings, this white paper equips you with the knowledge to navigate the evolving landscape of healthcare technology. Complete the form […]
Navigating the Patient Journey: Understanding, Challenges, and Solutions in Patient Journey Mapping
EVERSANA’s APAC Authors: Ankit Kulshrestha, Robin Arnold This POV explores the intricacies of Patient Journey Mapping, detailing its significance, challenges, and solutions. Patient journey mapping is a comprehensive discipline that traces a patient’s entire healthcare journey, from initial symptoms to treatment and beyond. Understanding this journey is imperative for pharmaceutical companies, enabling them to address challenges and optimize patient-centric solutions. The document highlights potential pitfalls in mapping patient journeys, emphasizing the need for market representation, segment differentiation, and a detailed examination of functional, emotional, and transactional experiences. Failure to link mapping to actionable mitigation measures poses a significant risk. Examining patient journeys solely from the patient’s perspective overlooks crucial viewpoints from […]
Reframing the Challenges of Access and ROI
Pharma companies today are being judged not just on their profitability for shareholders, but also on the extent to which their products are accessible to patients. Today’s Environmental, Social and Governance (ESG) investors want to see evidence of corporate responsibility, for which pharmaceuticals’ surrogate measure is access. While companies such as Novo Nordisk and UCB explicitly include access or related measures as direct performance indicators, eight of the top 20 companies are developing systematic access plans. GSK and Novartis have made specific quantitative commitments to increasing access for their products by 2025. While access has always been of interest as a metric, companies have been discouraged by the trade-off between […]
WEBINAR: Sustainability in Pharma: Access and Financial Returns
In addition to the global disruption caused by COVID-19, pharma faces additional pressure to adopt digital technologies, transform long-standing business practices, and accelerate timelines to deliver value for HCPs and patients. Not to mention, the specialty pipeline continues to grow, but therapies for rare diseases are facing significant access challenges. In this webinar, EVERSANA’s Rob Arnold, Executive Vice President for APAC, shares how we’re supporting global clients and patients with insights and proven commercialization strategies during this turning point in our industry. Watch his Pharma Japan presentation below! Learn more about how EVERSANA’s global commercial solutions provide the right strategies and tools to accelerate your speed to market. To learn […]
How Do You Know Your Portfolio Process Is Adding Value?
In 1998, Rob Arnold, Executive Vice President, teamed with some colleagues to publish an article in the Harvard Business Review that highlighted the practical results obtained by applying modern R&D portfolio thinking to SmithKline Beecham’s late-stage assets. SB publicly claimed that the review process had added $2.6 billion in value to the corporation. That team worked with most major pharma companies to apply similar principles in the 1990s, and huge value was unlocked using superior analytic and people process approaches. These approaches were developed to address the most significant challenge of the time: too many assets and not enough investment available. Industry challenges are different today, and more time is […]